Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/182875
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Atzeni, Fabiola | - |
dc.contributor.author | Masala, Ignazio Francesco | - |
dc.contributor.author | Rodríguez Carrió, Javier | - |
dc.contributor.author | Ríos Garcés, Roberto | - |
dc.contributor.author | Gerratana, Elisabetta | - |
dc.contributor.author | Corte La, Laura | - |
dc.contributor.author | Giallanza, Manuela | - |
dc.contributor.author | Nucera, Valeria | - |
dc.contributor.author | Riva, Agostino | - |
dc.contributor.author | Espinosa, Gerard | - |
dc.contributor.author | Cervera i Segura, Ricard, 1960- | - |
dc.date.accessioned | 2022-02-01T14:46:46Z | - |
dc.date.available | 2022-02-01T14:46:46Z | - |
dc.date.issued | 2021-02-16 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/2445/182875 | - |
dc.description.abstract | Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients | - |
dc.format.extent | 20 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm10040783 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2021, vol. 10, num. 4, p. 783 | - |
dc.relation.uri | https://doi.org/10.3390/jcm10040783 | - |
dc.rights | cc-by (c) Atzeni, Fabiola et al., 2021 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Pneumònia | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Pneumonia | - |
dc.title | The Rheumatology drugs for COVID-19 management: Which and when? | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 708241 | - |
dc.date.updated | 2022-02-01T14:46:46Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
708241.pdf | 629.07 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License